Shots:
Epitopea & Merck have entered into license & research collaboration agreement to discover Cryptigen tumor-specific antigens (TSAs) in an undisclosed solid tumor
As per the deal, Epitopea will receive an undisclosed upfront & ~$300M in milestones per product in exchange for Merck receiving exclusive development & commercialization rights to the TSA products identified…
